Alternate remedies with natural products provides unlimited opportunities for new drug development. These can be either as pure compounds or as standardized set of compounds. The phytochemicals and secondary metabolites are in great demand for screening bioactive compounds and plays an important role towards drug development. Natural products have many advantages over to synthetic chemical drugs. Helicobacter pylori (H. pylori) a Gram-negative bacteria has been classified as Class I carcinogen by World Health Organization in 1994. Current treatment regimens for H. pylori is ‘triple therapy’ administrated for two weeks which includes a combination of two antibiotics like Amoxicillin and Clarithromycin and a proton pump inhibitor (PPI) like Lansoprazole, and for ‘quadruple therapy’ in addition to antibiotics and a PPI, Bismuth is used. Antibiotic resistance can be named as the main factor for failure of treatment of H. pylori infection. The need of the hour is to develop a herbal remedy that could combat the growth of H. pylori. Probiotics can also be used as ‘feasible’ tool for H. pylori infection management. Present review is an attempt to briefly discuss about the pathogenicity, genetic predisposition, perturbation of gut microbiota due to antibiotic treatment and restoration of healthy gut microbiota with phytochemicals and probiotics.

中文翻译：

---

幽门螺杆菌：肠道微生物群的扰动和恢复

天然产物的替代疗法为新药开发提供了无限的机会。这些可以是纯化合物，也可以是标准化的一组化合物。植物化学物质和次生代谢物在筛选生物活性化合物方面需求量很大，并且在药物开发中发挥着重要作用。与合成化学药物相比，天然产物具有许多优势。幽门螺杆菌 (H. pylori) 是一种革兰氏阴性菌，已于 1994 年被世界卫生组织列为 I 类致癌物。目前幽门螺杆菌的治疗方案是“三联疗法”，持续两周，其中包括两种抗生素的组合，例如阿莫西林和克拉霉素以及兰索拉唑等质子泵抑制剂 (PPI)，对于除抗生素和 PPI 之外的“四联疗法”，还使用铋。抗生素耐药性可被称为幽门螺杆菌感染治疗失败的主要因素。当前的需要是开发一种可以对抗幽门螺杆菌生长的草药。益生菌也可用作幽门螺杆菌感染管理的“可行”工具。本综述试图简要讨论抗生素治疗引起的肠道微生物群的致病性、遗传易感性、扰动以及植物化学物质和益生菌对健康肠道微生物群的恢复。